Changgui Li

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang, Gang Zeng, Hongxing Pan et al. · The Lancet Infectious Diseases · 2020 · 1.5K citations · Full text

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Hui Wang, Yuntao Zhang, Baoying Huang et al. · Cell · 2020 · 796 citations · Full text

Vaccination, Vaccine Development, Immunology +7

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Shilong Yang, Yan Li, Lianpan Dai et al. · The Lancet Infectious Diseases · 2021 · 451 citations · Full text

Vaccination, Vaccine Safety, Vaccinology +7

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Bihua Han, Yufei Song, Changgui Li et al. · The Lancet Infectious Diseases · 2021 · 351 citations · Full text

Vaccination, Vaccine Safety, Vaccinology +8

A Novel Influenza A (H1N1) Vaccine in Various Age Groups

Fengcai Zhu, Hua Wang, Han-hua Fang et al. · New England Journal of Medicine · 2009 · 341 citations · Full text